See more : Tyranna Resources Limited (TYX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of BioPlus Acquisition Corp. (BIOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioPlus Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Sunfly Intelligent Technology Co., LTD (300423.SZ) Income Statement Analysis – Financial Results
- PT Matahari Putra Prima Tbk (MPPA.JK) Income Statement Analysis – Financial Results
- Jinlongyu Group Co., Ltd. (002882.SZ) Income Statement Analysis – Financial Results
- OneLink Corporation (OLNK) Income Statement Analysis – Financial Results
- Collective Mining Ltd. (CNL.TO) Income Statement Analysis – Financial Results
BioPlus Acquisition Corp. (BIOS)
About BioPlus Acquisition Corp.
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
| Metric | 2022 | 2021 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 708.90M | 817.20M | 935.60M | 982.20M | 984.10M | 842.20M | 662.60M | 0.00 | 1.64B | 1.33B | 1.40B | 1.20B | 1.15B | 1.07B | 630.50M | 588.80M | 576.60M | 456.60M | 369.80M | 377.40M | 451.10M | 242.30M | 283.20M | 213.90M | 109.30M | 100.00K |
| Cost of Revenue | 1.17M | 0.00 | 465.90M | 547.90M | 670.00M | 721.30M | 723.00M | 570.40M | 437.70M | 0.00 | 1.38B | 1.17B | 1.26B | 1.06B | 1.03B | 957.00M | 562.40M | 520.20M | 506.00M | 403.20M | 334.60M | 347.10M | 421.40M | 239.00M | 278.10M | 213.40M | 106.70M | 0.00 |
| Gross Profit | -1.17M | 0.00 | 243.00M | 269.30M | 265.60M | 260.90M | 261.10M | 271.80M | 224.90M | 0.00 | 260.40M | 157.80M | 142.20M | 137.00M | 119.60M | 116.20M | 68.10M | 68.60M | 70.60M | 53.40M | 35.20M | 30.30M | 29.70M | 3.30M | 5.10M | 500.00K | 2.60M | 100.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 34.28% | 32.95% | 28.39% | 26.56% | 26.53% | 32.27% | 33.94% | 0.00% | 15.89% | 11.87% | 10.14% | 11.44% | 10.38% | 10.83% | 10.80% | 11.65% | 12.24% | 11.70% | 9.52% | 8.03% | 6.58% | 1.36% | 1.80% | 0.23% | 2.38% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 47.30M | 63.30M | 66.00M | 83.60M | 319.40M | 254.00M | 198.50M | 0.00 | 226.30M | 140.60M | 129.10M | 125.30M | 129.20M | 109.30M | 52.80M | 50.60M | 45.90M | 38.50M | 33.90M | 28.00M | 23.10M | 19.10M | 11.60M | 8.00M | 5.30M | 100.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.17K | 162.43 | 47.30M | 63.30M | 66.00M | 83.60M | 319.40M | 254.00M | 198.50M | 0.00 | 226.30M | 140.60M | 129.10M | 125.30M | 129.20M | 109.30M | 52.80M | 50.60M | 45.90M | 38.50M | 33.90M | 28.00M | 23.10M | 19.10M | 11.60M | 8.00M | 5.30M | 100.00K |
| Other Expenses | 1.17M | 0.00 | 189.60M | 220.80M | 197.70M | 465.00M | 35.10M | 40.70M | 13.10M | 4.80M | 27.90M | 1.80M | 96.60M | 2.90M | 6.60M | 36.10M | 3.00M | 1.90M | 500.00K | -200.00K | 1.50M | 7.10M | 4.00M | 0.00 | 26.60M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.17M | 162.43 | 236.90M | 284.10M | 263.70M | 548.60M | 354.50M | 294.70M | 211.60M | 4.80M | 254.20M | 142.40M | 225.70M | 128.20M | 135.80M | 145.40M | 55.80M | 52.50M | 46.40M | 38.30M | 35.40M | 35.10M | 27.10M | 19.10M | 38.20M | 8.00M | 5.30M | 100.00K |
| Cost & Expenses | 1.17M | 162.43 | 702.80M | 832.00M | 933.70M | 1.27B | 1.08B | 865.10M | 649.30M | 4.80M | 1.63B | 1.31B | 1.49B | 1.19B | 1.17B | 1.10B | 618.20M | 572.70M | 552.40M | 441.50M | 370.00M | 382.20M | 448.50M | 258.10M | 316.30M | 221.40M | 112.00M | 100.00K |
| Interest Income | 3.17M | 9.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | -57.40M | -52.10M | -38.20M | -37.30M | -38.50M | 28.20M | 26.07M | 28.31M | -27.60M | -1.90M | -2.70M | -3.30M | -3.00M | -400.00K | -800.00K | -800.00K | -800.00K | -100.00K | 800.00K | 1.00M | 1.70M | 2.30M | 1.40M | 700.00K | 200.00K | 0.00 |
| Depreciation & Amortization | 228.49K | 236.56K | 23.60M | 27.73M | 21.55M | 22.74M | -81.10M | -16.10M | 73.07M | 15.88M | 12.33M | 5.03M | 6.40M | 7.09M | 10.86M | 9.92M | 5.03M | 5.08M | 6.06M | 6.36M | 4.88M | 3.22M | 1.69M | 1.09M | 780.00K | 370.00K | 90.00K | 0.00 |
| EBITDA | -1.17M | 9.49 | -84.90M | -24.97M | -56.15M | -335.76M | -174.60M | -39.00M | 86.37M | 39.39M | -36.67M | 16.63M | -82.50M | 9.39M | -11.44M | -19.98M | 15.73M | 19.48M | 28.66M | 21.36M | 3.98M | 420.00K | 7.69M | -10.11M | -29.62M | -5.73M | -2.21M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | -11.98% | -3.06% | -6.00% | -34.18% | -17.74% | -4.63% | 13.03% | 0.00% | -2.24% | 1.25% | -5.88% | 0.78% | -0.99% | -1.86% | 2.49% | 3.31% | 4.97% | 4.68% | 1.08% | 0.11% | 1.70% | -4.17% | -10.46% | -2.68% | -2.02% | 0.00% |
| Operating Income | -1.17M | -162.43 | -108.50M | -52.70M | -77.70M | -358.50M | -93.50M | -22.90M | 13.30M | 23.51M | -49.00M | 11.60M | -88.90M | 2.30M | -22.30M | -29.90M | 10.70M | 14.40M | 22.60M | 15.00M | -900.00K | -2.80M | 6.00M | -11.20M | -30.40M | -6.10M | -2.30M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -15.31% | -6.45% | -8.30% | -36.50% | -9.50% | -2.72% | 2.01% | 0.00% | -2.99% | 0.87% | -6.34% | 0.19% | -1.93% | -2.79% | 1.70% | 2.45% | 3.92% | 3.29% | -0.24% | -0.74% | 1.33% | -4.62% | -10.73% | -2.85% | -2.10% | 0.00% |
| Total Other Income/Expenses | 3.17M | 9.49 | 57.50M | -14.70M | 45.30M | 33.50M | -38.50M | -28.20M | -26.10M | -28.31M | 27.60M | 1.90M | 2.70M | 3.30M | 3.00M | 300.00K | 800.00K | 800.00K | 800.00K | 100.00K | -800.00K | -1.00M | -1.70M | -2.30M | -1.40M | -700.00K | -200.00K | 0.00 |
| Income Before Tax | 2.00M | -152.95 | -51.00M | -67.40M | -32.40M | -325.00M | -132.00M | -51.10M | -12.80M | -4.80M | -21.40M | 13.50M | -86.20M | 5.60M | -19.30M | -29.60M | 11.50M | 15.20M | 23.40M | 15.10M | -1.70M | -3.80M | 4.30M | -13.50M | -31.80M | -6.80M | -2.50M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -7.19% | -8.25% | -3.46% | -33.09% | -13.41% | -6.07% | -1.93% | 0.00% | -1.31% | 1.02% | -6.15% | 0.47% | -1.67% | -2.76% | 1.82% | 2.58% | 4.06% | 3.31% | -0.46% | -1.01% | 0.95% | -5.57% | -11.23% | -3.18% | -2.29% | 0.00% |
| Income Tax Expense | -3.17M | 9.49 | 600.00K | 63.60M | 2.00M | -21.50M | 11.40M | 2.50M | -4.40M | 28.31M | 47.70M | -40.60M | -12.20M | 2.30M | 19.00M | -5.70M | 4.50M | 6.10M | 4.70M | 900.00K | 100.00K | 1.00M | 1.70M | 2.30M | 1.40M | 700.00K | 200.00K | 0.00 |
| Net Income | 5.16M | -152.95 | -51.60M | -131.00M | -34.40M | -303.50M | -143.40M | -53.60M | -8.40M | -33.11M | -69.10M | 54.10M | -74.00M | 3.30M | -38.30M | -23.90M | 7.00M | 9.10M | 18.70M | 14.20M | -1.80M | -4.80M | 2.60M | -15.80M | -33.20M | -7.50M | -2.70M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | -7.28% | -16.03% | -3.68% | -30.90% | -14.57% | -6.36% | -1.27% | 0.00% | -4.22% | 4.07% | -5.28% | 0.28% | -3.32% | -2.23% | 1.11% | 1.55% | 3.24% | 3.11% | -0.49% | -1.27% | 0.58% | -6.52% | -11.72% | -3.51% | -2.47% | 0.00% |
| EPS | 0.01 | -0.02 | -0.40 | -1.06 | -0.37 | -4.42 | -2.09 | -0.83 | -0.15 | -0.60 | -1.37 | 1.36 | -1.93 | 0.09 | -1.03 | -0.70 | 0.31 | 0.40 | 0.79 | 0.64 | -0.09 | -0.26 | 0.16 | -1.25 | -3.46 | -1.60 | -0.60 | 0.00 |
| EPS Diluted | 0.01 | -0.02 | -0.40 | -1.06 | -0.37 | -4.42 | -2.09 | -0.83 | -0.15 | -0.60 | -1.37 | 1.36 | -1.93 | 0.09 | -1.03 | -0.70 | 0.31 | 0.40 | 0.79 | 0.64 | -0.09 | -0.26 | 0.16 | -1.25 | -3.46 | -1.60 | -0.60 | 0.00 |
| Weighted Avg Shares Out | 597.79M | 6.88K | 127.90M | 123.80M | 93.70M | 68.70M | 68.50M | 64.60M | 56.20M | 55.20M | 50.40M | 39.70M | 38.40M | 38.50M | 37.30M | 34.10M | 22.70M | 22.60M | 23.60M | 22.30M | 19.90M | 18.70M | 16.30M | 12.60M | 9.60M | 4.70M | 4.50M | 4.50M |
| Weighted Avg Shares Out (Dil) | 597.79M | 6.88K | 127.90M | 123.80M | 93.70M | 68.70M | 68.50M | 64.60M | 56.20M | 55.20M | 50.40M | 39.70M | 38.40M | 38.50M | 37.30M | 34.10M | 22.70M | 22.60M | 23.60M | 22.30M | 19.90M | 18.70M | 16.30M | 12.60M | 9.60M | 4.70M | 4.50M | 4.50M |
BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (“BIOS” or the “Company”) (Nasdaq: BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination...
Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation
- Transaction values Avertix at an enterprise value of $195 million - Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac events, including silent heart attacks
BioPlus Acquisition Corp. Announces Pricing of Upsized $200,000,000 Initial Public Offering
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market...
Option Care Health Completes Reverse Stock Split and Ticker Symbol Change
BANNOCKBURN, Ill., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today that it has completed the reverse...
Option Care Health Selected by Highmark as Preferred Provider of Hemophilia Treatment
National leader in treating bleeding disorders offers personalized, high-quality patient care National leader in treating bleeding disorders offers personalized, high-quality patient care
Option Care Health to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
BANNOCKBURN, Ill.--(BUSINESS WIRE)--Option Care Health Inc. (NASDAQ: BIOS), the nation’s largest independent national provider of home and alternate site infusion services, today announced that John Rademacher, Chief Executive Officer, will participate in a fireside chat on September 10 at the...
Option Care Health Receives Anticipated Nasdaq Notice
BANNOCKBURN, Ill.--(BUSINESS WIRE)--Option Care Health, Inc. (Nasdaq: BIOS) announced today that on August 7, 2019, it received a letter from the Nasdaq Staff informing it that, since the merger between Option Care Enterprises, Inc. and BioScrip, Inc. constituted a change...
Option Care and BioScrip Complete Merger to Form Option Care Health
BANNOCKBURN, Ill. & DENVER--(BUSINESS WIRE)--Option Care Enterprises, Inc. (“Option Care”) and BioScrip, Inc. (“BioScrip”) today announced the successful completion of their merger, which follows the satisfaction of the transaction’s closing conditions, including approval by BioScrip shareholders and the receipt of...
BioScrip Provides Update on Annual Form 10-K Filing Status
DENVER--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that it will be filing a Form 12b-25 with the U.S. Securities and Exchange Commission to automatically...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of BioScrip, Inc. -- BIOS
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of BioScrip, Inc. (NASDAQGM: BIOS) concerning possible violations of federal securities laws. On March 8, 2018, BioScrip released its preliminary fourth quarter and full year financial results and disclosed...
Source: https://incomestatements.info
Category: Stock Reports